The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.

OBJECTIVES To investigate the effectiveness of etanercept on axial manifestations of a group of patients with established psoriatic arthritis (PsA). METHODS This was a multicentre observational study. PsA was classified based on the CASPAR criteria. Inclusion criteria were refractory PsA with axial manifestations and suitability for anti TNF-α therapy. Effectiveness was defined according to the ASAS response criteria (BASDAI: 50% relative or absolute change of 20mm and expert opinion in favour of continuation), and on the improvements of BASFI, anthropometric measures, PASI, ESR and CRP at 12 months. PASI 50 and 75 were also assessed, as well as the ACR20 and ACR50 response criteria for patients with peripheral arthritis. Comparisons between baseline and after 12-month treatment were done using the Wilcoxon signed rank test for the end-points considered. RESULTS The study included 32 patients (25/7 M/F; median age 51yrs; 25th-75th percentiles: 34.5-58.7; median disease duration 14.5 yrs; 25th-75th percentiles: 9.2-17.00). Effectiveness of etanercept was observed in 72% of patients for the BASDAI (p<0.001), in 68% for the BASFI (p<0.001), in 76% for ESR (p<0.001) and in 68% of patients for CRP (p<0.01). The PASI improved in 72% of patients treated (p<0.0001), while PASI 50 and PASI 75 was reached in 81% and 55% of patients, respectively. ACR 20 and 50 was reached in 78 and 56% of patients with peripheral involvement respectively. CONCLUSIONS The present study has shown that etanercept is effective on axial manifestations of established PsA, confirming the positive effects of anti TNF-α therapy on clinical manifestations of the disease.

[1]  I. Olivieri,et al.  The Radiological Assessment of Axial Involvement in Psoriatic Arthritis , 2012, The Journal of Rheumatology. Supplement.

[2]  I. Olivieri,et al.  Beyond Early Diagnosis: Occult Psoriatic Arthritis , 2010, The Journal of Rheumatology.

[3]  B. Dijkmans,et al.  Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. , 2010, Clinical and experimental rheumatology.

[4]  J. Tasende,et al.  Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis , 2010, Arthritis care & research.

[5]  D. Symmons,et al.  Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register , 2009, Rheumatology.

[6]  A. Sanduzzi,et al.  Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs , 2010, Clinical Rheumatology.

[7]  D. Gladman,et al.  Axial Psoriatic Arthritis: Update on a Longterm Prospective Study , 2009, The Journal of Rheumatology.

[8]  J. Kalden,et al.  Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.

[9]  I. Olivieri,et al.  Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis , 2009, The Journal of Rheumatology.

[10]  I. Olivieri,et al.  Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology. , 2008, Clinical and experimental rheumatology.

[11]  D. Gladman.  Axial disease in psoriatic arthritis , 2007, Current rheumatology reports.

[12]  J. Braun,et al.  Quality indicators, guidelines and outcome measures in ankylosing spondylitis. , 2007, Clinical and experimental rheumatology.

[13]  D. Gladman,et al.  International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. , 2007, The Journal of rheumatology.

[14]  A. Gottlieb,et al.  Consensus on a core set of domains for psoriatic arthritis. , 2007, The Journal of rheumatology.

[15]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[16]  A. Kavanaugh,et al.  Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis , 2006, Current opinion in rheumatology.

[17]  K. de Vlam,et al.  Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. , 2006, Rheumatology.

[18]  I. Olivieri,et al.  Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. , 2006, Clinical and experimental rheumatology.

[19]  W. Taylor,et al.  Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. , 2005, The Journal of rheumatology.

[20]  M. Dougados,et al.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[21]  V. Wright,et al.  Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? , 1998, Annals of the rheumatic diseases.

[22]  K. Pile,et al.  Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. , 1991, British journal of rheumatology.

[23]  D. Gladman,et al.  Psoriatic spondyloarthropathy: a long term prospective study. , 1988, Annals of the rheumatic diseases.

[24]  A. Calin,et al.  Clinical history as a screening test for ankylosing spondylitis. , 1977, JAMA.